Matt Gaughenbaugh
About Matt Gaughenbaugh
Matt Gaughenbaugh is an Enterprise Executive at Cerebras Systems, specializing in multi-modality AI applications and life sciences. He has a background in sales and account management, with prior roles at OMG, Inc. and Qualtrics.
Work at Cerebras Systems
Matt Gaughenbaugh serves as an Enterprise Executive at Cerebras Systems, a position he has held since 2023. In this role, he focuses on leveraging AI technologies to address complex challenges within the life sciences sector. His responsibilities include engaging with stakeholders and promoting the application of AI in various projects, particularly those involving multi-modality in AI applications.
Previous Experience at OMG, Inc.
Prior to his current role, Matt Gaughenbaugh worked at OMG, Inc. in two capacities. He served as a Field Sales Representative from 2012 to 2019, where he gained extensive experience in sales operations. He then transitioned to the role of Territory Sales Manager for one year, from 2018 to 2019, further developing his skills in managing sales territories and client relationships.
Experience at Qualtrics
Matt Gaughenbaugh worked at Qualtrics as a Senior Account Executive from 2019 to 2023. During his tenure, he was responsible for managing client accounts and driving sales initiatives. His experience at Qualtrics contributed to his expertise in account management and understanding client needs in the technology sector.
Education and Expertise
Matt Gaughenbaugh earned a Bachelor of Science (BS) degree from The Ohio State University, completing his studies from 2007 to 2011. His educational background provides a foundation for his work in AI applications, particularly in the life sciences field. He focuses on projects that enhance drug discovery efforts through the use of genomic language models and conversational AI platforms.
Focus on AI and Life Sciences
In his professional endeavors, Matt Gaughenbaugh partners with visionaries to apply artificial intelligence to complex challenges in life sciences. He is involved in initiatives that aim to accelerate drug discovery and make conversational AI platforms accessible to all team members within organizations. His engagement with generative AI and large language models reflects his commitment to advancing technology in the healthcare sector.